2004 Press Release

11.25.2004 Santen Purchase Own Shares on Market by ToSTNet-2[PDF:16KB]

11.24.2004 Santen to Purchase Own Shares on Market by ToSTNet-2[PDF:18 KB]

11.09.2004 Santen to Terminate Sales of Ophthalmic Surgical Instruments

11.04.2004 Santen Announces Financial Results for the First Six Months ended September 30, 2004

11.04.2004 Santen Establishes New Retirement Benefit and Pension Program[PDF:35KB]

10.15.2004 Agreement Concerning Development of Novel Anti-rheumatic Agent Anti-APO-1 Antibody in Japan [PDF:38KB]

09.16.2004 Annual Report 2004 is now available on this Web site.

07.29.2004 Santen Announces Financial Results for the First Quarter of Fiscal Year 2004 (Three Months Ended June 30, 2004)[Report]

07.20.2004 Santen Launches Anti- rheumatic METOLATE® Tablets 2mg [PDF:16KB]

07.12.2004 Agreement Concerning Glaucoma and Ocular Hypertension Treatment RESCULA® Eye Drops[PDF:22KB]

07.05.2004 Notice on the Exercise Price of Stock Options (Stock Acquisition Rights)[PDF:15KB]

06.25.2004 Santen Hosts the 92nd Annual General Meeting of Shareholders

06.25.2004 Notice on the Allotment of Stock Options (Stock Acquisition Rights)[PDF:12KB]

05.07.2004 Santen Announces Financial Results for the Year ended March 31, 2004 [PDF:57KB]

03.10.2004 Santen to Retire Treasury Stock [PDF:12KB]

03.10.2004 Revision of Performance Forecast [PDF:16KB]

03.10.2004 Santen Announces Proposed Dividends Change [PDF:13KB]

03.02.2004 Santen Receives FDA Approval of IQUIX, New Treatment for Sight-threatening Condition [PDF:19KB]

01.30.2004 Santen Announces Financial Results for the Nine Months Ended December 31, 2003